ArticleJournal of the American Academy of Dermatology2020
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review.Biomolecules · 2023Pooled it
- Dupilumab for the treatment of prurigo nodularis: A systematic review.Frontiers in immunology · 2023Pooled it
- Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Trial
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
- Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature.Dermatology and therapy · 2025Review
- Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.Postepy dermatologii i alergologii · 2025Article
- Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review.Frontiers in medicine · 2025Article
- A Case of Acquired Reactive Perforating Dermatosis with Complete Resolution of Eruptions on Upper and Lower Limbs During the Treatment of Diabetes Mellitus and Peripheral Artery Disease.Medicina (Kaunas, Lithuania) · 2024Article
- Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.International journal of molecular sciences · 2024Review
- Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.Journal of clinical medicine · 2024Article
- Integrative Approaches to Sleep Management in Skin Disease: Systematic Review.JMIR dermatology · 2023Review
- Risk of incident sleep disorders in patients with prurigo nodularis: A population-level analysis using The Health Improvement Network.JAAD international · 2023Article
- Effectiveness of Dupilumab for Chronic Prurigo in Chinese Patients: A Real-World Case Series Study.Clinical drug investigation · 2023Article
- Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.Nature reviews. Drug discovery · 2023Review
- Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life.Dermatology (Basel, Switzerland) · 2023Article
- Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation.Frontiers in immunology · 2023Article
- Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment.International journal of molecular sciences · 2022Review
- Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases.Nature reviews. Immunology · 2022Review
- Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?Dermatology practical & conceptual · 2022Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.
objectiveTo describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies.
methodsRetrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks.
resultsTwenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy. LIMITATIONS: Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.
conclusionDupilumab was proven effective in reducing itch and improving CNPG skin lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.